000 | nab a22 7a 4500 | ||
---|---|---|---|
999 |
_c16895 _d16895 |
||
003 | PC16895 | ||
005 | 20220603134724.0 | ||
008 | 220603b xxu||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_9389 _aMartínez López, Joaquín _eHematología y Hemoterapia |
||
100 |
_93057 _aLópez Anglada, Lucía _eHematología y Hemoterapia |
||
100 |
_9390 _aCedena Romero, María Teresa _eHematología |
||
100 |
_93058 _aSáez Gómez, María Auxiliadora _eHematología y Hemoterapia |
||
100 |
_91468 _aRapado Martínez, Inmaculada _eInstituto de Investigación i+12 |
||
100 |
_93059 _aCueto Felgueroso, Cecilia _eHematología y Hemoterapia |
||
100 |
_9388 _aLahuerta Palacios, Juan José _eHematología y Hemoterapia |
||
245 | 0 | 0 |
_aCritical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. _h[artículo] |
260 |
_bBlood, _c2015 |
||
300 | _a126(7):858-62. | ||
500 | _aFormato Vancouver: Martínez López J, Paiva B, López Anglada L, Mateos MV, Cedena T, Vidríales MB et al; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015 Aug 13;126(7):858-62. | ||
501 | _aPMID: 26089396 PMC4543912 | ||
504 | _aContiene 21 referencias | ||
520 | _aStringent complete response (sCR) criteria are used in multiple myeloma as a deeper response category compared with CR, but prospective validation is lacking, it is not always clear how evaluation of clonality is performed, and is it not known what the relative clinical influence is of the serum free light chain ratio (sFLCr) and bone marrow (BM) clonality to define more sCR. To clarify this controversy, we focused on 94 patients that reached CR, of which 69 (73%) also fulfilled the sCR criteria. Patients with sCR displayed slightly longer time to progression (median, 62 vs 53 months, respectively; P = .31). On analyzing this contribution to the prognosis of sFLCr or clonality, it was found that the sFLCr does not identify patients in CR at distinct risk; by contrast, low-sensitive multiparametric flow cytometry (MFC) immunophenotyping (2 colors), which is equivalent to immunohistochemistry, identifies a small number of patients (5 cases) with high residual tumor burden and dismal outcome; nevertheless, using traditional 4-color MFC, persistent clonal BM disease was detectable in 36% of patients, who, compared with minimal residual disease-negative cases, had a significantly inferior outcome. These results show that the current definition of sCR should be revised. | ||
710 |
_9297 _aServicio de Hematología y Hemoterapia |
||
710 |
_9625 _aInstituto de Investigación imas12 |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16895.pdf _ySolicitar documento |
||
942 |
_2ddc _cART _n0 |